Shire writes off a shot at long-act­ing he­mo­phil­ia drug af­ter small study flops

When Shire took over Bax­al­ta, it ac­quired a pro­gram in de­vel­op­ment that used the tech­nol­o­gy from near­by Lex­ing­ton, MA-based Xe­net­ic Bio­sciences to stretch SHP656 in­to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER